Consumer
Nestle Targets Consumers Losing Weight as Sales Growth Ebbs
- Shares have dropped on concern obesity drugs may dent demand
- CEO Schneider says dieters need nutrition-enriched products
This article is for subscribers only.
Nestle SA is working on products designed to complement a new class of weight-loss drugs after revenue growth weakened to the slowest pace in almost three years.
Recent declines in food stocks has been partly blamed on the meteoric boom in GLP-1 diabetes treatments, namely Ozempic and Wegovy, which curb users appetites and help them to lose significant amounts of weight. Soaring demand for these drugs have made their Danish owner Novo Nordisk A/S the most valuable company in Europe.